Our laboratory showed that oncogenic NOTCH1 regulates MYC expression and leukemia-initiating cell activity and demonstrated the efficacy of NOTCH1 inhibitors in pre-clinical T-ALL models (6–9). The gene discussed is NOTCH1; the disease is acute lymphoblastic leukemia.